Vermillion Posts $431K in Q1 Revenue, Anticipates Two Peer-Reviewed Articles on OVA1
May 13, 2011
Vermillion Posts $431K in Q1 Revenue, Anticipates Two Peer-Reviewed Articles on OVA1
The papers, one of which was published this week online, have been accepted for publication in the June edition of Obstetrics & Gynecology and could be key to driving increased adoption of the test by physicians, said Laura Havrilesky, a gynecological oncologist at Duke University.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Vermillion Performs 3,920 OVA1 Tests in Q2, But Revenues Fall 9 Percent on Drop in Licensing Income
August 5, 2011 / ProteoMonitor - Vermillion Posts $344,000 in Q2 Revenues, Including First Sales of OVA1 Test
August 13, 2010 / ProteoMonitor - Vermillion Signs Better Revenue-Splitting Deal with Quest for OVA1, Lowers Full-Year Sales Guidance
November 12, 2010 / ProteoMonitor - Vermillion Granted US Patent Supporting PAD Biomarker
September 17, 2010 / ProteoMonitor - UPDATE: Vermillion Repays Quest $5.9M, Ending Companies' Credit Agreement
October 19, 2012 / ProteoMonitor